Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Cannabis Bioscience Internatnl Hlgs Inc (PK:CBIH)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEC Form 4 filings for CBIH*US within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Mar 20, 2024 08:00 ET
CBIH Commences Clinical Trials of Osteoarthritis Injection "Orthocann"
Houston, Texas--(Newsfile Corp. - March 20, 2024) - Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH) has announced the enrollment of the first patient for the clinical trial of its new intra-articular cannabinoid-based injection for knee osteoarthritis. The company plans to test the product on its first participant, and after careful collection and analysis of clinical outcomes, start enrollment of a bigger sample of patients to administer the treatment and further evaluate its efficacy.
Read full article
Mar 06, 2024 08:00 ET
CBIH Announces the Retirement of One Billion Shares
Houston, Texas--(Newsfile Corp. - March 6, 2024) - Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH) announces that Dante Picazo, its chief executive officer, is contributing one billion shares of his common stock to the Company. These shares will be retired and have the status of authorized and unissued shares. As a result of this contribution, the number of the Company's outstanding shares has been reduced to approximately 9.4 billion. Since current management assumed control of the Company in 2019, its members have contributed 5.5 billion shares to the Company for no or nominal consideration. The shares have a market price of approximately $5 million, valued at the closing price of $0.0009 on March 5, 2024. The Company believes that Mr. Picazo's contribution will increase shareholder value.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
-0.16
--
--
Price to Sales - TTM
0.13
4.12
3.21
Price to Book - most recent quarter
0.00
2.11
2.13
Price to Cash Flow per share - TTM
0.79
11.64
13.71
Price to Free Cash Flow per share - TTM
--
26.08
23.67
See all valuations

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Cannabis Bioscience International Holdings, Inc. provides educational and other services to the cannabis industry. The Company provides educational systems focused on medical cannabis in cities throughout the United States and six countries in Latin America. The Company's segments include Pharmacology University Business and Alpha Research Business. Through the Pharmacology University Business, the Company provides knowledge and promotes professionalism in the rapidly growing worldwide cannabis industry through education in and research about the medical properties and healing virtues of this substance. Through the Alpha Research Business, based in Houston, Texas, the Company offers specialized services in all therapeutic areas of clinical trials and has conducted over 20 clinical trials for Sponsors and CROs. These trials have included drugs relating to diseases in the areas of asthma, allergies, renal disorders, neurology disorders, cardiac and vascular disorders and others.

See business summary

 

Twitter

Search (past week) for $CBIH

  • No tweets found